The first PI3K pathway-targeted agents approved for cancer treatment were the “rapalogs” Everolimus (RAD001) and Temsirolimus (CCI779), both with the capacity to inhibit the functional protein complex mTORC1. The gene discussed is PIK3CA; the disease is cancer.